後期慢性腎臓病治療薬の世界市場レポート 2025年

後期慢性腎臓病治療薬市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.4％で、122億米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、精密医療アプローチの採用、再生医療への注目の高まり、患者中心のケア重視の高まり、腎臓病啓発のための世界の取り組みなどに起因しています。予測期間における主な動向としては、再生医療治療の拡大、CKD管理のための遠隔医療サービスの増加、併用療法の開発、早期介入戦略の重視、バイオマーカーに基づく診断への関心の高まりなどが挙げられます。

慢性腎臓病の有病率の高さは、後期慢性腎臓病治療薬市場の今後の成長を牽引すると予想されます。慢性腎臓病は、腎臓の構造と機能に影響を及ぼす幅広い疾患を包含します。後期慢性腎臓病治療薬は、患者の血圧を管理し、タンパク質の損失を減らすために利用され、腎臓障害の進行を遅らせ、症状を緩和し、合併症を予防するのに役立っています。例えば、2024年5月、米国の公衆衛生機関である疾病対策予防センター（CDC）は、米国成人の約14％、約3,550万人が慢性腎臓病を患っていると推定しています。したがって、慢性腎臓病の有病率が後期慢性腎臓病治療薬市場の成長を牽引しています。

糖尿病の有病率の増加は、後期慢性腎臓病（CKD）治療薬市場の今後の成長を牽引すると予想されます。糖尿病は血糖値の上昇を特徴とする慢性疾患で、心臓、血管、目、腎臓、神経に重大な障害を引き起こす可能性があります。糖尿病は慢性腎臓病発症の危険因子としてよく知られています。糖尿病患者、特に血糖値の管理が不十分な患者は、末期のCKDに進行するリスクが高いです。糖尿病の世界の有病率の上昇に伴い、CKD、特に進行期のCKDの発症率もそれに応じて上昇すると予想されます。例えば、2024年3月、英国政府部門のOffice for Health Improvement &Disparitiesは、2022年3月から2023年3月の間に、推奨される8つのケアプロセスをすべて受けている1型糖尿病患者の割合が22％増加し、2型糖尿病では21％増加したと報告しました。さらに、HbA1cの目標値を達成した患者の割合は37.9%に上昇し、全国糖尿病監査（NDA）が記録した最高値を更新しました。したがって、糖尿病の高い有病率が後期慢性腎臓病治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界後期慢性腎臓病治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の後期慢性腎臓病治療薬市場：成長率分析
• 世界の後期慢性腎臓病治療薬市場の実績：規模と成長, 2019-2024
• 世界の後期慢性腎臓病治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界後期慢性腎臓病治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の後期慢性腎臓病治療薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシウム拮抗薬
• ビタミンD
• ステロール
• カリウム結合剤
• カルシウム系リン酸結合剤
• 世界の後期慢性腎臓病治療薬市場適応症の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性腎臓病末期に伴う副甲状腺機能亢進症
• 慢性腎臓病末期に伴う高リン血症
• 慢性腎臓病末期における高カリウム血症
• 世界の後期慢性腎臓病治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の後期慢性腎臓病治療薬市場、カルシウム模倣薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シナカルセト
• エテルカルセチド
• 世界の後期慢性腎臓病治療薬市場、ビタミンDのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシトリオール
• ドキセルカルシフェロール
• パリカルシトール
• 世界の後期慢性腎臓病治療薬市場ステロールの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エルゴカルシフェロール
• コレカルシフェロール
• 世界の後期慢性腎臓病治療薬市場カリウム結合剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリスチレンスルホン酸ナトリウム
• パティロメル
• ジルコニウムシクロケイ酸ナトリウム
• 世界の後期慢性腎臓病治療薬市場、カルシウム系リン酸結合剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酢酸カルシウム
• 炭酸カルシウム

第7章 地域別・国別分析

• 世界の後期慢性腎臓病治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の後期慢性腎臓病治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 後期慢性腎臓病治療薬市場：競合情勢
• 後期慢性腎臓病治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• C.H. Boehringer Sohn AG & Co. KG
• Amgen Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Kyowa Kirin Co Ltd.
• OPKO Health Inc.
• Evotec SE
• Ionis Pharmaceuticals Inc.
• Akebia Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 後期慢性腎臓病治療薬市場2029：新たな機会を提供する国
• 後期慢性腎臓病治療薬市場2029：新たな機会を提供するセグメント
• 後期慢性腎臓病治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Late-stage chronic kidney disease drugs are medications designed to treat end-stage chronic kidney disease, aiming to improve patients' quality of life by arresting the progression of the disease and, in some cases, preventing or delaying the need for dialysis or a kidney transplant.

The primary product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics, for instance, constitute a class of medications that enhance signaling and reduce parathyroid hormone (PTH) levels by activating the calcium-sensing receptor allosterically. These drugs address various indications related to late-stage chronic kidney disease, such as hyperparathyroidism, hyperphosphatemia, and hyperkalemia. The distribution channels for these drugs typically include hospital pharmacies, online pharmacies, and retail pharmacies.

The late stage chronic kidney disease drugs market research report is one of a series of new reports from The Business Research Company that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.08 billion in 2024 to $7.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $12.2 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for CKD management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.

The high prevalence of chronic kidney diseases is expected to drive the growth of the late-stage chronic kidney disease drug market in the future. Chronic kidney diseases encompass a wide range of conditions that impact the structure and function of the kidneys. Drugs for late-stage chronic kidney disease are utilized to manage blood pressure in patients and reduce protein loss, helping to slow the progression of kidney impairment, alleviate symptoms, and prevent complications. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, estimated that approximately 14% of U.S. adults-around 35.5 million people-are living with chronic kidney diseases. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.

The increasing prevalence of diabetes is anticipated to drive the growth of the late-stage chronic kidney disease (CKD) drug market in the future. Diabetes is a chronic condition marked by elevated blood glucose levels, which can cause significant damage to the heart, blood vessels, eyes, kidneys, and nerves. It is a well-recognized risk factor for developing chronic kidney disease. Individuals with diabetes, particularly those with poorly managed blood sugar levels, face a heightened risk of progressing to late-stage CKD. As the global prevalence of diabetes rises, the incidence of CKD, especially in its advanced stages, is expected to rise correspondingly. For example, in March 2024, the Office for Health Improvement & Disparities, a UK government department, reported that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of patients achieving target HbA1c levels rose to 37.9%, marking the highest level recorded by the National Diabetes Audit (NDA). Therefore, the high prevalence of diabetes is propelling the growth of the late-stage chronic kidney disease drug market.

Product innovation emerges as a prominent trend gaining traction in the late-stage chronic kidney disease drug market, with major companies actively developing new drugs to maintain their market positions. For example, in February 2022, Bayer, a leading Germany-based pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. Finerenone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for patients with type two diabetes and chronic renal disease. The drug works by preventing the overactivation of the mineralocorticoid receptor (MR), believed to be a factor in the development of chronic kidney disease (CKD) and cardiovascular harm.

Key players in the late-stage chronic kidney disease drugs market are advancing technologies such as continuous subcutaneous infusion methods to enhance treatment effectiveness, improve patient outcomes, and streamline the drug development process. Continuous subcutaneous infusion technology provides a steady delivery of medication through a small device implanted under the skin, ensuring consistent therapeutic levels and increasing patient adherence. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA (for levodopa/foscarbidopa). This product facilitates a continuous infusion of levodopa, which is essential for maintaining stable dopamine levels in the bloodstream. This is vital for effectively managing symptoms, as it prolongs the duration of "on" time-periods when symptoms are well-managed-while reducing "off" time when symptoms reappear.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. This strategic acquisition strengthens AstraZeneca's cardiorenal pipeline by adding CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed to treat chronic kidney disorders. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, is the developer of baxdrostat. The acquisition enhances AstraZeneca's position in the late-stage chronic kidney disease drug market.

Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc

North America was the largest region in the late stage chronic kidney disease drugs market in 2024. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on late stage chronic kidney disease drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for late stage chronic kidney disease drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The late stage chronic kidney disease drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders
• 2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism; Late Stage Chronic Kidney Disease Induced Hyperphosphatemia; Late Stage Chronic Kidney Disease Induced Hyperkalemia
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Calcimimetics: Cinacalcet; Etelcalcetide
• 2) By Vitamin D: Calcitriol; Doxercalciferol; Paricalcitol
• 3) By Sterols: Ergocalciferol; Cholecalciferol
• 4) By Potassium Binders: Sodium Polystyrene Sulfonate; Patiromer; Sodium Zirconium Cyclosilicate
• 5) By Calcium-Based Phosphate Binders: Calcium Acetate; Calcium Carbonate
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Late Stage Chronic Kidney Disease Drugs Market Characteristics

3. Late Stage Chronic Kidney Disease Drugs Market Trends And Strategies

4. Late Stage Chronic Kidney Disease Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Late Stage Chronic Kidney Disease Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Late Stage Chronic Kidney Disease Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Late Stage Chronic Kidney Disease Drugs Market Growth Rate Analysis
• 5.4. Global Late Stage Chronic Kidney Disease Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Late Stage Chronic Kidney Disease Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Late Stage Chronic Kidney Disease Drugs Total Addressable Market (TAM)

6. Late Stage Chronic Kidney Disease Drugs Market Segmentation

• 6.1. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders
• 6.2. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalemia
• 6.3. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cinacalcet
• Etelcalcetide
• 6.5. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcitriol
• Doxercalciferol
• Paricalcitol
• 6.6. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergocalciferol
• Cholecalciferol
• 6.7. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Polystyrene Sulfonate
• Patiromer
• Sodium Zirconium Cyclosilicate
• 6.8. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Acetate
• Calcium Carbonate

7. Late Stage Chronic Kidney Disease Drugs Market Regional And Country Analysis

• 7.1. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market

• 8.1. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Late Stage Chronic Kidney Disease Drugs Market

• 9.1. China Late Stage Chronic Kidney Disease Drugs Market Overview
• 9.2. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Late Stage Chronic Kidney Disease Drugs Market

• 10.1. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Late Stage Chronic Kidney Disease Drugs Market

• 11.1. Japan Late Stage Chronic Kidney Disease Drugs Market Overview
• 11.2. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Late Stage Chronic Kidney Disease Drugs Market

• 12.1. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Late Stage Chronic Kidney Disease Drugs Market

• 13.1. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Late Stage Chronic Kidney Disease Drugs Market

• 14.1. South Korea Late Stage Chronic Kidney Disease Drugs Market Overview
• 14.2. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Late Stage Chronic Kidney Disease Drugs Market

• 15.1. Western Europe Late Stage Chronic Kidney Disease Drugs Market Overview
• 15.2. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Late Stage Chronic Kidney Disease Drugs Market

• 16.1. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Late Stage Chronic Kidney Disease Drugs Market

• 17.1. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Late Stage Chronic Kidney Disease Drugs Market

• 18.1. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Late Stage Chronic Kidney Disease Drugs Market

• 19.1. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Late Stage Chronic Kidney Disease Drugs Market

• 20.1. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market

• 21.1. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market Overview
• 21.2. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Late Stage Chronic Kidney Disease Drugs Market

• 22.1. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Late Stage Chronic Kidney Disease Drugs Market

• 23.1. North America Late Stage Chronic Kidney Disease Drugs Market Overview
• 23.2. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Late Stage Chronic Kidney Disease Drugs Market

• 24.1. USA Late Stage Chronic Kidney Disease Drugs Market Overview
• 24.2. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Late Stage Chronic Kidney Disease Drugs Market

• 25.1. Canada Late Stage Chronic Kidney Disease Drugs Market Overview
• 25.2. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Late Stage Chronic Kidney Disease Drugs Market

• 26.1. South America Late Stage Chronic Kidney Disease Drugs Market Overview
• 26.2. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Late Stage Chronic Kidney Disease Drugs Market

• 27.1. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Late Stage Chronic Kidney Disease Drugs Market

• 28.1. Middle East Late Stage Chronic Kidney Disease Drugs Market Overview
• 28.2. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Late Stage Chronic Kidney Disease Drugs Market

• 29.1. Africa Late Stage Chronic Kidney Disease Drugs Market Overview
• 29.2. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape And Company Profiles

• 30.1. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape
• 30.2. Late Stage Chronic Kidney Disease Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Late Stage Chronic Kidney Disease Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Eli Lilly and Company
• 31.5. C.H. Boehringer Sohn AG & Co. KG
• 31.6. Amgen Inc.
• 31.7. Novo Nordisk A/S
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Otsuka Pharmaceutical Co. Ltd.
• 31.10. Takeda Pharmaceutical Company Limited
• 31.11. Kyowa Kirin Co Ltd.
• 31.12. OPKO Health Inc.
• 31.13. Evotec SE
• 31.14. Ionis Pharmaceuticals Inc.
• 31.15. Akebia Therapeutics Inc.

32. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market

34. Recent Developments In The Late Stage Chronic Kidney Disease Drugs Market

35. Late Stage Chronic Kidney Disease Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer